Celularity Reiterates Strategic Partnership with NEXGEL to Develop Biomaterials Franchise

Celularity has reiterated its strategic commercialization partnership with NEXGEL, focusing on building a biomaterials franchise with established commercial products and new 510(k) pathway product opportunities. The partnership includes licensed products like Biovance, Biovance 3L, Natalin, Acelagraft, Interfyl, and Centaflex, as well as pipeline programs SPARK, FUSE, and ORCHID. Celularity will manufacture the licensed products at its FDA-compliant facility in New Jersey. The transaction is expected to close by April 15, 2026.